The BCH blog Vector talks about the progress of rFIXFc, a recombinant hybrid of Factor IX and an Fc receptor fragment, a new long lasting clotting factor which recently passed a phase 3 clinical trial. The technology is the result of a collaboration Wayne Lencer, a researcher at Boston Children’s Hospital, Richard Blumberg from Brigham and Women’s Hospital (BWH) and Associate Professor of Biology Neil Simister from Brandeis. We’re all excited to see this technology emerge from the labs, and progress to the point where it’s poised to make a significant impact in the lives of hemophilia patients.